LIMNW Liminatus Pharma, Inc. - Warrants
$0.06
Price · May 19, 2026
Fundamentals as of Mar 31, 2026
52W Range
$0–$0
14% of range
Analyst Rating
—
Price Target
—
P/E (TTM)
—
ROE
109.6%
Net Profit Margin
—
LIMNW Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$0.06
Market Cap
—
P/E (TTM)
—
EPS (TTM)
$-0.43
Revenue (TTM)
—
Div Yield
—
ROE
109.6%
Debt/Equity
-0.1
52W Range
$0 – $0
LIMNW Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
$-0.43
2024-12-31
→
2025-12-31
Free Cash Flow
$-10M
2025-12-31
→
2025-12-31
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
LIMNW
Peer Median
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
LIMNW
Peer Median
ROA
-344.7%
—
ROE
109.6%
—
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
LIMNW
Peer Median
Debt / Equity
-0.1
—
Current Ratio
0.0
—
Quick Ratio
0.0
—
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
LIMNW
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
LIMNW
Peer Median
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 12
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| R&D Expense | · | $3M | |
| SG&A Expense | $3M | $644.6K | |
| Operating Expenses | $3M | $3M | |
| Operating Income | $-3M | $-3M | |
| Interest Income | $76.6K | $122.5K | |
| Other Non-op | $-7M | $-216.4K | |
| Net Income | $-10M | $-4M | |
| EPS (Basic) | $-0.43 | $-0.20 | |
| EPS (Diluted) | $-0.43 | $-0.20 | |
| Shares (Basic) | 23,753,561 | 17,500,000 | |
| Shares (Diluted) | 23,753,561 | 17,500,000 | |
| EBITDA | $-3M | · |
Balance Sheet 17
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Cash & Equivalents | $337.7K | $56.3K | |
| Prepaid Expense | $162.9K | $155.5K | |
| Current Assets | $500.6K | $5M | |
| PP&E (Net) | $12.2K | $941 | |
| Total Assets | $512.8K | $5M | |
| Accounts Payable | $582.2K | $1M | |
| Accrued Liabilities | · | $805 | |
| Short-term Debt | $1M | $20M | |
| Current Liabilities | $10M | $25M | |
| Total Liabilities | $10M | $25M | |
| Total Debt | $1M | · | |
| Common Stock | $2.7K | $1.8K | |
| Paid-in Capital | $29M | $9M | |
| Retained Earnings | $-39M | $-29M | |
| Stockholders' Equity | $-10M | $-19M | |
| Liabilities + Equity | $512.8K | $5M | |
| Shares Outstanding | 27,064,633 | 17,500,000 |
Cash Flow 7
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Operating Cash Flow | $-10M | $-1M | |
| CapEx | $13.1K | · | |
| Investing Cash Flow | $-788.1K | $-3M | |
| Financing Cash Flow | $11M | $4M | |
| Net Change in Cash | $281.3K | $-378.1K | |
| Taxes Paid | $0 | $0 | |
| Free Cash Flow | $-10M | · |
Profitability 2
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| ROA | -344.7% | · | |
| ROE | 109.6% | · |
Liquidity & Solvency 3
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Current Ratio | 0.0 | · | |
| Quick Ratio | 0.0 | · | |
| Debt / Equity | -0.1 | · |
Valuation (TTM) 1
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Net Income TTM | $-10M | · |
Income Statement 12
| Metric | Trend | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| R&D Expense | · | · | · | · | $0 | |
| SG&A Expense | $884.2K | $701.2K | $1M | · | $167.1K | |
| Operating Expenses | $884.2K | $701.2K | $1M | · | $167.1K | |
| Operating Income | $-1M | $-701.2K | $-1M | $-255 | $-2M | |
| Interest Income | $0 | $0 | $24.4K | · | $43.5K | |
| Other Non-op | $-7M | $-1M | $1M | · | $-62.7K | |
| Net Income | $-8M | $-2M | $113.3K | $-327.5K | $-229.8K | |
| EPS (Basic) | $2.19 | $-0.07 | $0.00 | $-2.55 | $2.35 | |
| EPS (Diluted) | $2.19 | $-0.07 | $0.00 | $-2.55 | $2.35 | |
| Shares (Basic) | -26,555,285 | 27,007,568 | 23,301,178 | 100 | -17,500,100 | |
| Shares (Diluted) | -26,555,285 | 27,007,568 | 23,301,178 | 100 | -17,500,100 | |
| EBITDA | · | $-701.2K | $-1M | $-255 | · |
Balance Sheet 17
| Metric | Trend | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $337.7K | $724.5K | $1M | · | $56.3K | |
| Prepaid Expense | $162.9K | $478.9K | $444.1K | · | $155.5K | |
| Current Assets | $500.6K | $1M | $2M | · | $5M | |
| PP&E (Net) | $12.2K | $12.8K | $198 | · | $941 | |
| Total Assets | $512.8K | $1M | $2M | · | $5M | |
| Accounts Payable | $582.2K | $559.2K | $431.9K | · | $1M | |
| Accrued Liabilities | · | · | · | $1.1K | · | |
| Short-term Debt | $1M | $1M | $1M | · | $20M | |
| Current Liabilities | $10M | $3M | $11M | · | $25M | |
| Total Liabilities | $10M | $3M | $11M | $1.1K | $25M | |
| Total Debt | · | $1M | $1M | · | · | |
| Common Stock | $2.7K | $2.7K | $2.6K | $0 | $1.8K | |
| Paid-in Capital | $29M | $29M | $20M | $10 | $9M | |
| Retained Earnings | $-39M | $-31M | $-29M | $-1.1K | $-29M | |
| Stockholders' Equity | $-10M | $-2M | $-9M | $-1.1K | $-19M | |
| Liabilities + Equity | $512.8K | $1M | $2M | · | $5M | |
| Shares Outstanding | 27,064,633 | 27,064,633 | 26,014,633 | · | 17,500,000 |
Cash Flow 5
| Metric | Trend | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $-386.8K | $-600.6K | $-9M | $0 | $-140.7K | |
| CapEx | $0 | · | · | · | · | |
| Investing Cash Flow | $0 | $-13.1K | $-200.0K | · | $-550.0K | |
| Financing Cash Flow | $0 | $0 | $10M | · | $700.0K | |
| Net Change in Cash | $-386.8K | $-613.7K | $1M | $0 | $9.3K |
Profitability 2
| Metric | Trend | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| ROA | · | -271.6% | 11.9% | · | · | |
| ROE | · | 221.6% | -2.6% | 48.1% | · |
Liquidity & Solvency 3
| Metric | Trend | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Current Ratio | · | 0.4 | 0.2 | · | · | |
| Quick Ratio | · | 0.3 | 0.1 | · | · | |
| Debt / Equity | · | -0.9 | -0.2 | · | · |
Valuation (TTM) 1
| Metric | Trend | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Net Income TTM | · | $-3M | $-2M | $-4M | · |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Income Statement
| 2025-12-31 | 2024-12-31 | |
|---|---|---|
| Net Income | $-10M | $-4M |
| Diluted EPS | $-0.43 | $-0.20 |
Balance Sheet
| 2025-12-31 | 2024-12-31 | |
|---|---|---|
| Debt / Equity | -0.1 | — |
| Current Ratio | 0.0 | — |
| Quick Ratio | 0.0 | — |
Cash Flow
| 2025-12-31 | 2024-12-31 | |
|---|---|---|
| Free Cash Flow | $-10M | — |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.